New Tools for Identifying, Tracking, and Isolating Human Progenitor Cells
识别、追踪和分离人类祖细胞的新工具
基本信息
- 批准号:7538303
- 负责人:
- 金额:$ 23.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-01 至 2009-11-28
- 项目状态:已结题
- 来源:
- 关键词:AcidsAddressAdultAntigensBacteriaBacteriophagesBindingBiological ModelsBlood VesselsCardiovascular DiseasesCardiovascular systemCell LineCell LineageCell SeparationCell TransplantationCellsClinicalConditionConfocal MicroscopyDegenerative DisorderDevelopmentDevelopmental BiologyDiabetes MellitusDiseaseEmbryoEndothelial CellsExcisionFGF2 geneFibroblast Growth Factor 2FibroblastsFluorescent ProbesFutureGoalsHarvestHourHumanIncubatedInfectionInjuryLabelLibrariesLicensingMacular degenerationMammalian CellMarket ResearchMethodsMonitorMultipotent Stem CellsNamesNatural regenerationNumbersPECAM1 geneParkinson DiseasePatientsPatternPeptidesPhage DisplayPhasePhase I Clinical TrialsPluripotent Stem CellsPolymerase Chain ReactionPopulationProcessPublic HealthQuantum DotsReagentRecoveryResearchResearch PersonnelSomatic CellSorting - Cell MovementSourceSpecificitySpinal cord injuryStagingStaining methodStainsStandards of Weights and MeasuresStem Cell ResearchStem cellsSurfaceTechnologyTestingTherapeuticTimeUncertaintyUnited States National Institutes of HealthWA09 Cell LineWound Healingadult stem cellbasecell typecommercializationcostcost effectivedaydesirehuman embryonic stem cellimmunocytochemistryinduced pluripotent stem cellinterestmonolayernew technologynovelnovel strategiespeptide Aprogenitorprotein aminoacid sequencescale upstemsuccesssynthetic peptidetime usetoolvector
项目摘要
DESCRIPTION (provided by investigator):
Human embryonic stem (hES) cells offer a potentially unlimited source of replacement cells for treating human degenerative diseases such as cardiovascular disease, macular degeneration, diabetes, Parkinson's disease, Alzheimers, as well as wound healing and spinal cord injury to name a few. In addition, advances in reprogramming somatic cells (induced pluripotent stem (iPS) cells) are a potential future source of patient specific pluripotent cells. Near term, these recent advances will no doubt increase the number of research grade ES-like cell lines dramatically and thus increase the market for research tools to identify, track and isolate progenitors of differentiated cell types of therapeutic interest. The directed differentiation of pluripotent stem cells to a desired differentiated cell type is generally inefficient often yielding only a few percent of the starting cells. Moreover, hES cells are difficult to grow on a large scale. Thus there is a need for reagents that identify progenitors of useful cell types that can be isolated and expanded before differentiation to allow cost effective scale up and increase the yield of differentiated product. Moreover, such reagents would be valuable research reagents for basic stem cell research and developmental biology. We propose here to develop a novel technology platform called time-lapse phage display for identifying progenitor cell binding peptides for use as tools to target, track, and isolate progenitors of therapeutically useful cells. In phase 1, we will test the feasibility of the technology by isolating peptides that target progenitors of CD31 (PECAM1) positive cells of endothelial lineage that we will derive from hES cells (NIH registered line WA09). The resulting peptides will be characterized for specificity and used to trace the lineage of the targeted progenitor cells. In phase II, we will use the technology to identify peptides for additional progenitors primarily of cardiovascular as well as other lineages. The use of the peptides for cell tracking and isolation will be optimized. Near term revenue will be generated through the commercialization of the peptides as reagents such as conjugated fluorescent probes and kits for progenitor identification, cell lineage tracking, and cell isolation. Selected peptides will be used internally to develop regenerative therapies of interest to ACT such as ischemic and cardiovascular disease and other peptides will be commercialized by licensing to corporate partners. We anticipate the technology proposed here will be generally applicable for identifying peptides that target progenitors derived from hES cells as well as other types of pluripotent or multipotent stem cells including induced iPS and adult stem cells. PUBLIC HEALTH RELEVANCE: Human embryonic stem (hES) cells provide a potentially unlimited source of pluripotent cells for treating human injury and disease because of their ability to continually self renew as well as differentiate into virtually any mature cell type. Additional sources of ES-like cells from reprogrammed adult cells may soon prove to be more cost-effective and less restrictive than their embryonic counterparts. However, regardless of the source of pluripotent cells, a key problem remains of how to obtain commercial quantities of clinical grade cells for transplantation. Moreover the optimal cells for transplantation in most cases have yet to be determined. We propose to address these issues by developing tools to identify, track, and isolate progenitor cells derived from pluripotent hES cells. We will initially use a novel peptide selection method called time-lapse phage display to identify peptides that target progenitors of human vascular cells and characterize the peptides for cell-specific targeting, cell isolation, and their ability to track the progenitors as they differentiate. The long term goals are to apply the proposed technology to identifying progenitors of cardiovascular and other cell lineages for therapeutic development and to commercialize the resulting cell targeting reagents, cell tracking and cell isolation kits.
描述(调查员提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dana Larocca其他文献
Dana Larocca的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dana Larocca', 18)}}的其他基金
Reagents for Targeted Ablation of Residual Contaminating Pluripotent Stem Cells
用于残留污染多能干细胞靶向消融的试剂
- 批准号:
8786795 - 财政年份:2013
- 资助金额:
$ 23.25万 - 项目类别:
Reagents for Targeted Ablation of Residual Contaminating Pluripotent Stem Cells
用于残留污染多能干细胞靶向消融的试剂
- 批准号:
8455044 - 财政年份:2013
- 资助金额:
$ 23.25万 - 项目类别:
Rapid Multiplexed Nanoprobe Assays for Pluripotent Stem Cell Differentiation
用于多能干细胞分化的快速多重纳米探针测定
- 批准号:
8592883 - 财政年份:2013
- 资助金额:
$ 23.25万 - 项目类别:
Rapid Multiplexed Nanoprobe Assays for Pluripotent Stem Cell Differentiation
用于多能干细胞分化的快速多重纳米探针测定
- 批准号:
8787873 - 财政年份:2013
- 资助金额:
$ 23.25万 - 项目类别:
Functional Selection of Novel Ligands from the Neuroendocrine Secretome
神经内分泌分泌组中新型配体的功能选择
- 批准号:
8003211 - 财政年份:2010
- 资助金额:
$ 23.25万 - 项目类别:
Double-Gated Selection of Ligands that Target Surface Markers of Differentiation
针对分化表面标记的配体的双门选择
- 批准号:
7671588 - 财政年份:2009
- 资助金额:
$ 23.25万 - 项目类别:
Antibodies Targeting Novel Surface Antigens on Pluripotent Stem Cell Derivatives
针对多能干细胞衍生物上新型表面抗原的抗体
- 批准号:
7748045 - 财政年份:2009
- 资助金额:
$ 23.25万 - 项目类别:
Defining Therapeutic Potential of Clonal Stem Cell Populations using Targeted Nan
使用靶向纳米粒子确定克隆干细胞群的治疗潜力
- 批准号:
7405115 - 财政年份:2008
- 资助金额:
$ 23.25万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 23.25万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 23.25万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 23.25万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 23.25万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 23.25万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 23.25万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 23.25万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 23.25万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 23.25万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 23.25万 - 项目类别:
Research Grant